

Topical Collection

Treatment of Hepatocellular Carcinoma and Cholangiocarcinoma

Message from the Collection Editor

In this Special Issue are summarized the current indications to different therapeutic options for hepatocellular carcinoma (HCC) and cholangiocarcinoma and more recent results are presented, according to the technologic advancements acquired in recent years. Novel treatment options for patients with HCC and cholangiocarcinoma have been introduced in the last few years, including percutaneous therapies, such as microwave ablation, cryoablation, and intra-arterial treatments such as drug-eluting bead chemoembolization, balloon-assisted chemoembolization, and radioembolization. The most advanced surgical approaches are also described. Systemic therapy of both tumors is also presented, with a special focus on immunotherapy. Advanced imaging analysis, such as radiomics, is presented, which can help in better evaluating the response to therapy and, therefore, allowing a better patient selection.

Collection Editor

Dr. Cristina Mosconi

Radiology Unit, Department of Radiology Policlinico di Sant'Orsola IRCCS, Azienda Ospedaliero, Universitaria di Bologna via Albertoni 15, 40138 Bologna, Italy



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/56699

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)